secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYBLEU Inc (—)
CIK:        0001818674
Form:       8-K
Filed at:   2024-04-18T23:59:59+00:00
Accession:  0001607062-24-000126
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 1.02, 2.01, 3.02, 5.01, 5.02, 9.01, 2.1
LLM model:  deepseek-v4-flash:cloud@v2

Worldwide Holdings acquires control of SYBLEU; new CEO appointed
----------------------------------------------------------------

- Purchaser acquired 88,789,000 shares via note conversion for $458,499 and 6,210,790 shares from sellers for $1.00.
- Previous sole director Joseph Vaini resigned; Jeremy Davey named Chairman/CEO, Laman Milner President, John Clark Secretary.
- Company terminated obligations under agreements with Timothy Foat, DYO Biotechnologies, and amended Zander Biologics agreement.
- Change in control effective April 15, 2024; noteholders include Zander Therapeutics, Zander Biologics, Bostonia Partners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818674/000160706224000126/0001607062-24-000126-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818674/000160706224000126/sybleu041724form8k.htm
  HTML page:      https://secwatch.observer/filing/0001607062-24-000126

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer